Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diperoxochloric acid - DermaTools

Drug Profile

Diperoxochloric acid - DermaTools

Alternative Names: CL05; DermaPro; DPOCL; Woxheal

Latest Information Update: 13 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DermaTools
  • Developer Centaur Pharmaceuticals; DermaTools
  • Class Antiulcers; Disinfectants; Small molecules
  • Mechanism of Action Cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Diabetic foot ulcer
  • Phase II/III Leg ulcer
  • Discontinued Burns

Most Recent Events

  • 02 Jul 2019 Chemical structure information added
  • 27 Jun 2019 DermaTools Biotech GmbH completes a phase II trial in Diabetic foot ulcer in Estonia and Latvia (EudraCT2017-004527-67)
  • 09 Aug 2017 CytoTools plans a phase II/III trial for Venous leg ulcer in Europe (Intralesional) (CytoTools pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top